A study published in PLOS Pathogens by Itai Yechezkel, Netanel Tzarum and colleagues, working across laboratories including those of Sarel J. Fleishman and Mansun Law, addresses this question at the level of atomic detail. The team focused on a striking feature of the human antibody response to hepatitis C: the bnAbs that neutralize the virus most broadly are heavily biased toward antibodies encoded by the VH1–69 germline gene segment. This bias is not a quirk of statistics. VH1–69-encoded antibodies share a hydrophobic framework region that is well suited to engaging a conserved patch on the E2 glycoprotein, and multiple independently evolved patients have converged on this solution. If nearly every successful neutralizing response passes through a VH1–69 precursor, the authors reasoned, then an effective vaccine must be able to engage the unmutated, germline-version B cell receptors built from that gene segment. Only then could the vaccine trigger the right naive B cells and set affinity maturation on the right path.

The problem was that nobody knew precisely how those germline precursors bound E2. Mature bnAbs have been structurally characterized in complex with E2 for years, but affinity maturation reshapes antibody paratopes substantially, and mature binding modes do not necessarily reflect what the naive receptor can achieve. A germline B cell receptor is typically flexible, low in affinity and geometrically imprecise, and many viral glycoproteins hide their conserved epitopes so thoroughly that naive receptors simply cannot reach them. This is the classic immunological hurdle behind germline-targeting vaccine strategies, the approach famously pursued for HIV-1, where engineered immunogens must first bind germline precursors and then shepherd them through sequential rounds of maturation. Whether the hepatitis C E2 core domain could even be recognized by a germline VH1–69 antibody was an open and consequential question.

Yechezkel, Maimon and their colleagues answered it by reverting several VH1–69-encoded hepatitis C bnAbs to their inferred germline sequences and examining how these reverted antibodies interact with the E2 core domain. The technique of germline reversion is a standard tool in the field: because the true naive ancestors of mature bnAbs are rarely captured directly, researchers infer the unmutated common ancestor from the mature sequence and reconstruct it, accepting that the inference may be imperfect but that it approximates the starting point of the maturation pathway. The team then solved high-resolution structures of these germline-reverted antibodies in complex with the E2 core, allowing a direct, residue-by-residue comparison with the mature antibody structures already on record.

The result was unexpectedly encouraging. The germline-reverted antibodies recognized the E2 core domain in a manner closely resembling the binding mode of their mature descendants. The conserved epitope features that mature bnAbs exploit, including the contacts that anchor the antibody to the E2 surface, were already accessible to the unmutated receptors. In structural terms, the key interactions did not have to be invented during affinity maturation; they were present from the start, and maturation refined and strengthened a pre-existing engagement rather than building it from scratch. This is a fundamentally different situation from pathogens such as HIV-1, where germline precursors often require purpose-built engineered immunogens to bind their target epitope at all. For hepatitis C, the conserved E2 epitope appears to be, in effect, visible to the naive immune repertoire.

That finding carries immediate implications for immunogen design. If germline VH1–69 receptors can already engage the E2 core with the correct geometry, then a vaccine based on a stabilized E2 core scaffold has a plausible path to triggering the right B cells without radical engineering of the epitope itself. The structural analysis also clarified which residues and contacts define the conserved mode of engagement, giving designers a map of what must be preserved and what can be modified to tune affinity, stability and presentation. The authors could therefore move from observation to engineering, using the structural insights to design E2 variants intended to enhance interactions with germline antibodies while maintaining the conformational integrity of the antigen.

The engineering effort produced a nuanced outcome. The designed E2 variants did show increased affinity for the germline-reverted antibodies, confirming that the structural map could be used productively to improve binding in biochemical assays. However, when the team tested whether the improved variants engaged naive B cells more effectively, the designs did not deliver the expected gain. Affinity, in other words, was not the limiting factor. This distinction matters because germline-targeting strategies ultimately depend on activating naive B cells in vivo, a process governed not only by binding affinity but by B cell receptor signaling thresholds, receptor mobility, avidity effects, competition from off-target B cells and the presentation context of the immunogen. A variant that binds a purified reverted antibody more tightly may still fail to recruit the corresponding naive B cell population if the bottleneck lies elsewhere.

The authors interpret this as a key constraint on germline-targeting approaches for hepatitis C, and the lesson likely generalizes. Optimizing biochemical affinity is a necessary but insufficient step in rational vaccine design; the immunogen must also present the epitope in a multivalent, stable and appropriately spaced format that satisfies the activation requirements of naive B cells. It also highlights a subtlety of germline reversion itself: inferred germline antibodies are approximations, and the true naive receptors expressed on B cells in a vaccinated individual may differ in ways that shift the binding landscape. The gap between a reverted antibody in a crystal structure and a naive B cell receptor on a resting lymphocyte is precisely where many germline-targeting programs have stumbled, and the hepatitis C field now has a concrete demonstration of that gap.

Nevertheless, the study substantially advances the rational design agenda for an HCV vaccine. It establishes that the conserved epitope on the E2 core is germline-accessible, which removes one of the most daunting obstacles facing germline-targeting strategies. It defines the structural principles governing how VH1–69 precursors engage E2, providing a template for iterative immunogen improvement. And it identifies, through the failure of the affinity-enhanced designs to improve naive B cell engagement, the next problem that must be solved: translating strong biochemical binding into effective B cell activation, likely through careful control of antigen valency, nanoparticle presentation and adjuvant context. The path from these findings to a licensed vaccine remains long, but the study converts an open question about germline recognition into a defined set of design principles, which is exactly what a rational vaccinology effort requires.

The broader context underscores the urgency. With millions of chronic infections worldwide and antiviral cure rates that do nothing to prevent reinfection, a prophylactic hepatitis C vaccine would transform global health. The convergence of structural biology, computational protein engineering and B cell immunology exemplified by this work reflects a maturing discipline in which vaccine candidates are designed against explicit structural hypotheses and tested against measurable immunological benchmarks. For hepatitis C, the demonstration that germline VH1–69 antibodies see the E2 core much as their mature descendants do is a genuine milestone, and the constraints it reveals about naive B cell engagement now set the agenda for the next generation of E2-based immunogens.

Subject of Research: Structural basis of germline broadly neutralizing antibody recognition of the hepatitis C virus E2 envelope glycoprotein for rational vaccine design

Article Title: Structural and biochemical insights into HCV envelope proteins for germline-targeting vaccines

Article References: Yechezkel, I., Maimon, H. E., Tennenhouse, A., Chen, F., Tarabih, H., Weisz, J., Fraenkel, R., Fleishman, S. J., Law, M., & Tzarum, N. (2026). Structural and biochemical insights into HCV envelope proteins for germline-targeting vaccines. PLOS Pathogens, 22(10), e1014651. https://doi.org/10.1371/journal.ppat.1014651

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014651

Keywords: hepatitis C virus, E2 glycoprotein, broadly neutralizing antibodies, VH1-69, germline targeting, vaccine design, structural biology, cryo-electron microscopy, protein engineering, B cell receptors, immunogens, PLOS Pathogens